title: BRAF-inhibition and tumor immune suppression.
abstract: As BRAFV600E-inhibitors become standard treatment for many metastatic melanoma patients, research has begun to elucidate their impact on the tumor immune landscape. Here, we highlight our recent studies demonstrating the ability of melanoma cell-intrinsic BRAFV600E-inhibition to selectively reduce intratumoral immunosuppressive cell populations and enhance antitumor CD8+T-cell immunity.
authors.affiliation: Department of Microbiology and Immunology; Geisel School of Medicine at Dartmouth; Dartmouth-Hitchcock Medical Center ; Lebanon, NH USA.
authors.forename: Shannon M
authors.initials: SM
authors.lastname: Steinberg
authors.affiliation: Department of Microbiology and Immunology; Geisel School of Medicine at Dartmouth; Dartmouth-Hitchcock Medical Center ; Lebanon, NH USA ; The Norris-Cotton Cancer Center; Dartmouth-Hitchcock Medical Center ; Lebanon, NH USA.
authors.forename: Mary Jo
authors.initials: MJ
authors.lastname: Turk
keywords: BRAF; CD8 T cells; MDSC, myeloid-derived suppressor cell; TME, tumor microenvironment; Treg, regulatory T cell; melanoma; myeloid-derived suppressor cells; regulatory T cells